Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Avogaro

Showing results (1-10 of 426) with videos related to

Pageof 43
Sort By:
The Lancet. Diabetes & Endocrinology|March 8, 2025
What does renal failure teach us about our National Health System?Angelo Avogaro
European Journal of Clinical Investigation|February 7, 2026
Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesityAngelo Avogaro
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|February 27, 2004
[Diabetes and multimetabolic syndrome]Angelo Avogaro
Metabolic Syndrome and Related Disorders|June 13, 2017
Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269-275)Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|January 28, 2015
[Hypoglycemia and cardiovascular risk]Angelo Avogaro
European Journal of Internal Medicine|April 10, 2021
SGLT2 inhibitors: Do we need other evidences?Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 9, 2008
[Glucagon-like peptide-1: pleiotropic effects on the cardiovascular system]Angelo Avogaro
Endocrine|June 3, 2024
Diabetes and obesity: the role of stress in the development of cancerAngelo Avogaro
Journal of Diabetes and Its Complications|February 22, 2011
Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83)Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|March 3, 2011
[Glucagon like peptide-1 and the cardiovascular system: pathophysiological mechanisms]Angelo Avogaro
Pageof 43

Showing results (1-10 of 426) with videos related to

Sort By:
Pageof 43
The Lancet. Diabetes & Endocrinology|March 8, 2025
What does renal failure teach us about our National Health System?Angelo Avogaro
European Journal of Clinical Investigation|February 7, 2026
Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesityAngelo Avogaro
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|February 27, 2004
[Diabetes and multimetabolic syndrome]Angelo Avogaro
Metabolic Syndrome and Related Disorders|June 13, 2017
Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269-275)Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|January 28, 2015
[Hypoglycemia and cardiovascular risk]Angelo Avogaro
European Journal of Internal Medicine|April 10, 2021
SGLT2 inhibitors: Do we need other evidences?Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|December 9, 2008
[Glucagon-like peptide-1: pleiotropic effects on the cardiovascular system]Angelo Avogaro
Endocrine|June 3, 2024
Diabetes and obesity: the role of stress in the development of cancerAngelo Avogaro
Journal of Diabetes and Its Complications|February 22, 2011
Comments on the article "Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations" by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79-83)Angelo Avogaro
Giornale Italiano Di Cardiologia (2006)|March 3, 2011
[Glucagon like peptide-1 and the cardiovascular system: pathophysiological mechanisms]Angelo Avogaro
Pageof 43